Clenbuterol is a potent beta-2 agonist widely misused by professional athletes and bodybuilders. Information on clenbuterol associated adverse events is present in case reports and case series, though it may not be readily available. This systematic review aimed to critically evaluate the evidence of adverse events associated with clenbuterol among athletes. The search strategy was in accordance with PRISMA guidelines. Databases such as PubMed, Science Direct, Scopus, and Google Scholar were searched from 1990 to October 2021 to find out the relevant case reports and case series. There were 23 included studies. Using a suitable scale, the included studies’ methodological quality analysis was evaluated. In total, 24 athletes experienced adverse events. Oral ingestion of clenbuterol was the most preferred route among them. The daily administered dose of clenbuterol was ranging from 20 µg to 30 mg. Major adverse events experienced by athletes were supraventricular tachycardia, atrial fibrillation, hypotension, chest pain, myocardial injury, myocarditis, myocardial ischemia, myocardial infarction, cardiomyopathy, hepatomegaly, hyperglycemia, and death. The cardiac-related complications were the most commonly occurring adverse events. Clenbuterol is notorious to produce life-threatening adverse events including death. Lack of evidence regarding the performance-enhancing effects of clenbuterol combined with its serious toxicities questions the usefulness of this drug in athletes.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
All the required data are available with manuscript.
Hwang JH, Spurlock ME, Kube JC, Li XZ, Smith SB (2021) Characterization of β-adrenergic receptors in bovine intramuscular and subcutaneous adipose tissue: comparison of lubabegron fumarate with β-adrenergic receptor agonists and antagonists. J Anim Sci 99:1–12. https://doi.org/10.1093/jas/skab116
Kim H-K, Della-Fera MA, Hausman DB, Baile CA (2010) Effect of clenbuterol on apoptosis, adipogenesis, and lipolysis in adipocytes. J Physiol Biochem 66:197–203. https://doi.org/10.1007/s13105-010-0024-8
Yamamoto I, Iwata K, Nakashima M (1985) Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. J Pharmacobiodyn 8:385–391. https://doi.org/10.1248/bpb1978.8.385
Al-Majed AA, Khalil NY, Khbrani I, Abdel-Aziz HA (2017) Clenbuterol hydrochloride. profiles of drug substances, excipients and related methodology. Elsevier. 91–123.
Grimmer NM, Gimbar RP, Bursua A, Patel M (2016) Rhabdomyolysis secondary to clenbuterol use and exercise. J Emerg Med 50:e71–e74. https://doi.org/10.1016/j.jemermed.2015.09.006
Zerobin K, Kündig H (1980) The control of myometrial functions during parturition with Aβ2-mimeticcompound, PlanipartR. Theriogenology 14:21–35. https://doi.org/10.1016/0093-691X(80)90131-4
Spiller HA, James KJ, Scholzen S, Borys DJ (2013) A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst Abuse 34:306–312. https://doi.org/10.1080/08897077.2013.772083
Daubert GP, Mabasa VH, Leung VW, Aaron C (2007) Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol 3:56–60. https://doi.org/10.1007/bf03160909
Young J, Anwar A (2009) Strong diabetes. BMJ Case Rep 2009:bcr0820080708. https://doi.org/10.1136/bcr.08.2008.0708
Waight M, McGuinness W (2016) Case of low dose clenbuterol toxicity. BMJ Case Rep 2016:bcr2016215157. https://doi.org/10.1136/2Fbcr-2016-215157
WADA prohibited list January 2020. Available online: https://www.wada-ama.org/sites/default/files/wada_2020_english_prohibited_list_0.pdf (access on 30.12.2021). pp. WADA antidoping agency.
Prohibited and restricted drugs in food animals. pp. Food Animal Residue Avoidance Databank.
Parr MK, Koehler K, Geyer H, Guddat S, Schänzer W (2008) Clenbuterol marketed as dietary supplement. Biomed Chromatogr 22:298–300. https://doi.org/10.1002/bmc.928
Hieger MA, Emswiler MP, Maskell KF et al (2016) A case series of clenbuterol toxicity caused by adulterated heroin. J Emerg Med 51:259–261. https://doi.org/10.1016/j.jemermed.2016.05.047
Moriarty N, Attar N (2020) Clenbuterol-induced myocarditis: a case report. Eur J Case Rep Intern Med 7. 10.12890%2F2020_001662
Brett J, Dawson AH, Brown JA (2014) Clenbuterol toxicity: a NSW poisons information centre experience. Med J Aust 200:219–221. https://doi.org/10.5694/mja13.10982
Gojmerac T, Pleadin J, Zuric M, Mirko L, Stipica C (2002) Effects of repeated growth-promoting doses of clenbuterol on the hepatic function of female pigs. Vet Hum Toxicol 44:269–271
Burniston JG, Ng Y, Clark WA, Colyer J, Tan L-B, Goldspink DF (2002) Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol 93:1824–1832. https://doi.org/10.1152/japplphysiol.00139.2002
Chai J, Xu Q, Dai J, Liu R (2013) Investigation on potential enzyme toxicity of clenbuterol to trypsin. Spectrochim Acta A Mol Biomol Spectrosc 105:200–206. https://doi.org/10.1016/j.saa.2012.12.017
Tewari D, Samoilă O, Gocan D et al (2019) Medicinal plants and natural products used in cataract management. Front Pharmacol 10:466. https://doi.org/10.3389/fphar.2019.00466
Howick J, Chalmers I, Glasziou P et al (2011) Background document: explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence. University of Oxford, Centre for Evidence-Based Medicine, Oxford, UK
Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med 23:60–63. https://doi.org/10.1136/bmjebm-2017-110853
Report on medicines use during COVID-19 Pandemic, July 2020. Avalable online: https://www.aifa.gov.it/documents/20142/1202341/OsMedCovidEng.pdf (access on 04.02.22).
New drug approval 2016. available online:https://newdrugapprovals.org/2016/10/03/clenbuterol/ (access on 05.02.23) pp. Clenbuterol is approved in Germany for the treatment of asthma and COPD.
Kierzkowska B, Stanczyk J, Kasprzak JD (2005) Myocardial infarction in a 17-year-old body builder using clenbuterol. Circ J 69:1144–1146. https://doi.org/10.1253/circj.69.1144
Barbosa J, Cruz C, Martins J et al (2005) Food poisoning by clenbuterol in Portugal. Food Addit Contam 22:563–566. https://doi.org/10.1080/02652030500135102
Brambilla G, Cenci T, Franconi F et al (2000) Clinical and pharmacological profile in a clenbuterol epidemic poisoning of contaminated beef meat in Italy. Toxicol Lett 114:47–53
Sirvent P, Douillard A, Galbes O et al (2014) Effects of chronic administration of clenbuterol on contractile properties and calcium homeostasis in rat extensor digitorum longus muscle. PLoS One 9:100281. https://doi.org/10.1371/journal.pone.0100281
Thompson JA, Mirza MH, Barker SA, Morgan TW, Bauer RW, McConnico RS (2011) Clenbuterol toxicosis in three Quarter Horse racehorses after administration of a compounded product. J Am Vet Med Assoc 239:842–849. https://doi.org/10.2460/javma.239.6.842
Njoroge L, Koromia GA, Patel B (2019) Myocardial infarction associated with clenbuterol abuse in a 22-year-old college athlete. J Am Coll Cardiol 73:2859. https://doi.org/10.1016/S0735-1097(19)33465-5
Bonnar CE, Brazil JF, Okiro JO et al (2021) Making weight: acute muscle weakness and hypokalaemia exacerbated by thyrotoxicosis factitia in a bodybuilder. Endocrinol Diabetes Metab Case Rep 2021. https://doi.org/10.1530/edm-21-0060
Santos RP, Pereira A, Guedes H, Lourenço C, Azevedo J, Pinto P (2015) Anabolic drugs and myocardial infarction–a clinical case report. Arq Bras Cardiol 105:316–9. https://doi.org/10.5935/2Fabc.20150111
Huckins DS, Lemons MF (2013) Myocardial ischemia associated with clenbuterol abuse: report of two cases. J Emerg Med 44:444–449. https://doi.org/10.1016/j.jemermed.2012.02.057
Burniston JG, Chester N, Clark WA, Tan LB, Goldspink DF (2005) Dose-dependent apoptotic and necrotic myocyte death induced by the β2-adrenergic receptor agonist, clenbuterol. Muscle Nerve 32:767–774. https://doi.org/10.1002/mus.20407
Duncker DJ, Bache RJ (2008) Regulation of coronary blood flow during exercise. Physiol Rev 88:1009–1086. https://doi.org/10.1152/physrev.00045.2006
Mazzanti G, Di Sotto A, Daniele C et al (2007) A pharmacodynamic study on clenbuterol-induced toxicity: β1-and β2-adrenoceptors involvement in guinea-pig tachycardia in an in vitro model. Food Chem Toxicol 45:1694–1699. https://doi.org/10.1016/j.fct.2007.03.002
Goldstein DR, Dobbs T, Krull B, Plumb VJ (1998) DECA-it’s what’s for dinner. South Med J 91:780–784
Hoffman RJ, Hoffman RS, Freyberg CL, Poppenga RH, Nelson LS (2001) Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. J Toxicol Clin Toxicol 39:339–344. https://doi.org/10.1081/clt-100105152
El-Sherif N, Turitto G (2011) Electrolyte disorders and arrhythmogenesis. Cardiol J 18:233–245
Kintz P, Gheddar L, Ameline A et al (2019) Complete post-mortem investigations in a death involving clenbuterol after long-term abuse. J Anal Toxicol 43:660–665. https://doi.org/10.1093/jat/bkz058
Lehmann S, Thomas A, Schiwy-Bochat K-H et al (2019) Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). Forensic Sci Int 303:109925. https://doi.org/10.1016/j.forsciint.2019.109925
Hausmann R, Hammer S, Betz P (1998) Performance enhancing drugs (doping agents) and sudden death–a case report and review of the literature. Int J Legal Med 111:261–264. https://doi.org/10.1007/s004140050165
Griswold MK, Blohm E, Cross R, Boyer EW, Carey JL (2017) Unsuspected clenbuterol toxicity in a patient using intramuscular testosterone. Clin Pract Cases Emerg Med 1:197. https://doi.org/10.5811/2Fcpcem.2017.2.33318
Clore JN, Thurby-Hay L (2009) Glucocorticoid-induced hyperglycemia. Endocr Pract 15:469–474. https://doi.org/10.4158/ep08331.rar
Illera J, MartÝnez M (1998) The effect of clenbuterol on adrenal function in rats. Anlst 123:2521–2524
Liu Q, Zhang J, Guo W, Zhao Y, Hu X, Li N (2012) Identifying lipid metabolism genes in pig liver after clenbuterol administration. Front Biosci (Elite Ed) 4:2605–2616. https://doi.org/10.2741/e569
Woolum J, Mancuso N, Rutter PW, Baum RA, Akpunonu P (2020) Chomping at the bit: a descriptive report on pediatric clenbuterol ingestion. J Pharm Pract 33:386–389. https://doi.org/10.1177/0897190018823114
Bonney CF, Hatten B, Wang GS (2019) Toxicity from unintentional pediatric ingestion of a performance-enhancing drug: a case report with review of clenbuterol toxicity and treatment. J Emerg Med 57:e105–e108. https://doi.org/10.1016/j.jemermed.2019.06.016
Mascagni P, Melandro F, Larghi-Laureiro Z, Mennini G, Rossi M (2018) Spontaneous hepatic rupture in a bodybuilder: a case report and review of the literature. Rev Esp Enferm Dig 110:254–6. https://doi.org/10.17235/reed.2017.5103/2017
Abdulredha WS (2019) Effect of clenbuterol using as weight loose on liver enzymes and lipids profile. Iraq Med J 3.
Hartung R, Gerth J, Fünfstück R, Gröne HJ, Stein G (2001) End-stage renal disease in a bodybuilder: a multifactorial process or simply doping? Nephrol Dial Transplant 16:163–165. https://doi.org/10.1093/ndt/16.1.163
Dufayet L, Gorgiard C, Vayssette F, Barbet J, Hoizey G, Ludes B (2020) Death of an apprentice bodybuilder following 2, 4-dinitrophenol and clenbuterol intake. Int J Legal Med 134:1003–1006. https://doi.org/10.1007/s00414-020-02268-2
Boland DM (2020) Disposition of toxic drugs and chemicals in man, 12th Edition. J Anal Toxicol 44:e13-e. https://doi.org/10.1093/jat/bkaa121
Girault J, Gobin P, Fourtillan J (1990) Quantitative measurement of clenbuterol at the femtomole level in plasma and urine by combined gas chromatography/negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom 19:80–88
Quinley KE, Chen H-Y, Yang HS, Lynch KL, Olson KR (2016) Clenbuterol causing non–ST-segment elevation myocardial infarction in a teenage female desiring to lose weight: case and brief literature review. Am J Emerg Med 34:1739
World Anti-Doping Agency (WADA) World anti-doping code 2015 (with 2019 Amendments) (access on 01.February 2023).
World Anti-Doping Ageny (WADA). Stakeholder notice regarding meat contamination. 2019. Available online: http://www.wada-ama.org/sites/default/files/resources/files/2019-05-30-meat_contamination_notice_final.pdf (Access on 01.02.23).
Schlupp A, Anielski P, Thieme D, Müller R, Meyer H, Ellendorff F (2004) The β-agonist clenbuterol in mane and tail hair of horses. Equine Vet J 36:118–122
Gleixner A, Sauerwein H, Meyer H (1996) Detection of the anabolic beta 2-adrenoceptor agonist clenbuterol in human scalp hair by HPLC/EIA. Clin Chem 42:1869–1871
Vulić A, Pleadin J, Perši N, Stojković R, Ivanković S (2011) Accumulation of β-agonists clenbuterol and salbutamol in black and white mouse hair. J Anal Toxicol 35:566–570
Krumbholz A, Anielski P, Gfrerer L et al (2014) Statistical significance of hair analysis of clenbuterol to discriminate therapeutic use from contamination. Drug Test Anal 6:1108–1116
Machnik M, Geyer H, Horning S, Breidbach A, Delahaut P, Schänzer W (1999) Long-term detection of clenbuterol in human scalp hair by gas chromatography–high-resolution mass spectrometry. J Chromatogr B Biomed Sci Appl 723:147–155
WADA 2012 anti-doping testing figures. Available online:https://www.wada-ama.org/sites/default/files/resources/files/2012_anti-doping_testing_figures_en.pdf (Access on 02.02.2023).
WADA 2013 anti-doping testing figures. Available online:https://www.wada-ama.org/sites/default/files/resources/files/2013_anti-doping_testing_figures_en.pdf (Access on 02.02.2023).
WADA 2014 anti-doping testing figures. Available online:https://www.wada-ama.org/sites/default/files/resources/files/2014_anti-doping_testing_figures_en.pdf (Access on 02.02.2023).
WADA 2015 anti-doping testing figures. Available online:https://www.wada-ama.org/sites/default/files/resources/files/2015_anti-doping_testing_figures_en.pdf (Access on 02.02.2023).
WADA 2016 anti-doping testing figures. Available online:https://www.wada-ama.org/sites/default/files/resources/files/2016_anti-doping_testing_figures_en.pdf (Access on 02.02.2023).
WADA 2017 anti-doping testing figures. Available online:https://www.wada-ama.org/sites/default/files/resources/files/2017_anti-doping_testing_figures_en.pdf (Access on 02.02.2023).
WADA 2018 anti-doping testing figures. Available online: https://www.wada-ama.org/sites/default/files/resources/files/2018_testing_figures_report.pdf (Access on 02.02.2023).
WADA 2019 anti-doping testing figures. Available online:https://www.wada-ama.org/sites/default/files/resources/files/2019_anti-doping_testing_figures_en.pdf (Access on 02.02.2023).
WADA 2020 anti-doping testing figures. Available online:https://www.wada-ama.org/sites/default/files/resources/files/2020_anti-doping_testing_figures_en.pdf (Access on 02.02.2023).
WADA 2021 anti-doping testing figures. https://www.wada-ama.org/sites/default/files/2023-01/2021_anti-doping_testing_figures_en.pdf.
Mohamed RA, Elbialy ZI, Abd El Latif AS et al (2020) Dietary clenbuterol modifies the expression of genes involved in the regulation of lipid metabolism and growth in the liver, skeletal muscle, and adipose tissue of Nile tilapia (Oreochromis niloticus). Aquac Rep 17:100319. https://doi.org/10.1016/j.aqrep.2020.100319
Performance and image enhancing drugs July 2019. Available online: https://www.tga.gov.au/news/news/performance-and-image-enhancing-drugs (Access on 05.02.23).
Vlad RA, Hancu G, Popescu GC, Lungu IA (2018) Doping in sports, a never-ending story? Adv Pharm Bull 8:529
Clenbuterol - DEA diversion control division. available online: https://www.deadiversion.usdoj.gov/drug_chem_info/clenbuterol.pdf (access on 29.07.22).
Wiegand TJ (2010) Adulterated cocaine and lessons learned from the Jake walk blues. Springer
Estrada-Montoya M, González-Córdova A, Torrescano G, Camou J, Vallejo-Cordoba B (2008) Screening and confirmatory determination of clenbuterol residues in bovine meat marketed in the Northwest of Mexico. Cienc Tecnol Aliment 6:130–136. https://doi.org/10.1080/11358120809487637
Pino Scotto D (2015) Polypharmacy tra gli utenti di steroidi androgeni anabolizzanti: un metasynthesis descrittivo. Subst Abuse Treat Prev Policy 10:12. https://doi.org/10.1186/s13011-015-0006-5
Hemery D, Ogden G, Evans A (1990) Winning without drugs: the natural approach to competitive sport. Willow.
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10:1–11
Perera NJ, Steinbeck KS, Shackel N (2013) The adverse health consequences of the use of multiple performance-enhancing substances—a deadly cocktail. J Clin Endocrinol Metab 98:4613–4618. https://doi.org/10.1210/jc.2013-2310
Mayer KN, Wyder D, Spasic D, Herren T (2016) Severe rhinovirus pneumonia in a young woman taking performance-enhancing drugs. BMJ Case Rep 2016:bcr2015213836. https://doi.org/10.1136/bcr-2015-213836
Žlak N, Košuta D, Potisek M, Stevanović Ž (2018) Clenbuterol toxicity in a young male athlete. Toxin reviews 37:182–186
Li C, Adhikari BK, Gao L et al (2018) Performance-enhancing drugs abuse caused cardiomyopathy and acute hepatic injury in a young bodybuilder. Am J Men’s Health 12:1700–1704. https://doi.org/10.1177/1557988318783504
Shafrir A, Leibowitz DW, Alcalai R, Elitzur Y, Muszkat M (2019) Myocardial injury induced by the long acting beta2 adrenergic agonist clenbuterol. Cardiol Cardiovasc Med 3:186–92. https://doi.org/10.26502/fccm.92920066
CDSCO, Clenbuterol hydrochloride solution for injection 30mcg/ml. https://cdscoonline.gov.in/CDSCO/Drugs. (access on 03.02.23).
List of most commonly encountered drugs currently controlled under the misuse of drugs legislation 8 August 2022. Available online: https://www.gov.uk/government/publications/controlled-drugs-list--2. (access on 23.09.22).
(2022) Health Canada. Policy for the importation or sale of active pharmaceutical ingredients for veterinary use POL-0018. Available online: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/hpfb-dgpsa/pdf/compli-conform/pol_0018-eng.pdf (access on September 20122).
China bans clenbuterol tablets. Available Online: https://www.thepigsite.com/news/2011/10/china-bans-clenbuterol-tablets-1#:~:text=CHINA%20%2D%20China%20has%20banned%20the,on%20Friday%20(30%20September) (access on 29.07.22).
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kumari, S., Pal, B., Sahu, S.K. et al. Adverse events of clenbuterol among athletes: a systematic review of case reports and case series. Int J Legal Med 137, 1023–1037 (2023). https://doi.org/10.1007/s00414-023-02996-1